Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension
Lauren Brash, Gareth D. Barnes, Melanie J. Brewis, A. Colin Church, Simon J. Gibbs, Luke S.G.E. Howard, Geeshath Jayasekera, Martin K. Johnson, Neil McGlinchey, Joelle Onorato, Joanne Simpson, Colin Stirrat, Stephen Thomson, Geoffrey Watson, Martin R. Wilkins, Carrie Xu, David J. Welsh, David E. Newby and Andrew J. Peacock
Hemodynamic changes during infusion of (Pyr1)apelin-13 (solid squares) or matched saline placebo (open squares) in patients with pulmonary arterial hypertension who are (A) on treatment with PDE5 inhibitors or (B) not on treatment with PDE5 inhibitors. Data are reported as mean ± SEM. *p = 0.049, **p = 0.0127, *** p = 0.0042, §p = 0.0039, §§p = 0.0017, #p = 0.0011, ##p = 0.0003, 2-way analysis of variance with post hoc Bonferroni tests. Abbreviations as in Figure 1.